



## **SUPERGENICS BERHAD**

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

### **INTERIM FINANCIAL STATEMENTS FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2020**

#### **CHARACTERISTICS OF THE LEAP MARKET OF BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)**

THE LEAP MARKET HAS BEEN POSITIONED AS A MARKET DESIGNED TO ACCOMMODATE CORPORATIONS TO WHICH A HIGHER INVESTMENT RISK MAY BE ATTACHED THAN OTHER CORPORATIONS LISTED ON THE ACE MARKET OR MAIN MARKET OF BURSA SECURITIES. IT IS A QUALIFIED MARKET WHICH IS MEANT MAINLY FOR SOPHISTICATED INVESTORS ONLY. ONLY EXISTING SECURITIES HOLDERS AND SOPHISTICATED INVESTORS ARE ALLOWED TO PARTICIPATE IN CORPORATE EXERCISES UNDERTAKEN BY SUPERGENICS BERHAD (“SGBHD” OR THE “COMPANY”). SOPHISTICATED INVESTORS SHOULD BE AWARE OF THE POTENTIAL RISKS OF INVESTING IN SUCH CORPORATIONS AND SHOULD MAKE THE DECISION TO INVEST ONLY AFTER DUE AND CAREFUL CONSIDERATION.

# SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

## UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2020

### CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	INDIVIDUAL 6 Months Ended		CUMULATIVE YTD	
	31 Dec 2020 RM'000	31 Dec 2019 RM'000	31 Dec 2020 RM'000	31 Dec 2019 RM'000
Revenue	3,509	7,435	5,133	11,011
Cost of sales	(1,945)	(4,890)	(3,337)	(7,398)
<b>Gross profit</b>	<b>1,564</b>	<b>2,545</b>	<b>1,796</b>	<b>3,613</b>
Other operating income	245	1	264	1
Operating and administrative expenses	(3,166)	(702)	(4,032)	(1,511)
Share of associate's results	(94)	-	(94)	-
<b>Profit/(loss) from operations</b>	<b>(1,451)</b>	<b>1,844</b>	<b>(2,066)</b>	<b>2,103</b>
Finance costs	(149)	(114)	(308)	(153)
<b>Profit/(loss) before taxation</b>	<b>(1,600)</b>	<b>1,730</b>	<b>(2,374)</b>	<b>1,950</b>
Taxation	191	(369)	191	(409)
<b>Total comprehensive profit/(loss)</b>	<b>(1,409)</b>	<b>1,361</b>	<b>(2,183)</b>	<b>1,541</b>
<b>Total comprehensive profit/(loss) attributable to :</b>				
Owners of the parent	(1,409)	1,361	(2,183)	1,541
	<b>(1,409)</b>	<b>1,361</b>	<b>(2,183)</b>	<b>1,541</b>
<b>(Loss)/earnings per-share</b>	<b><u>sen</u></b>	<b><u>sen</u></b>	<b><u>sen</u></b>	<b><u>sen</u></b>
Basic	<b>(1.52)</b>	6.82	<b>(2.36)</b>	15.31
Diluted	<b>N/A</b>	N/A	<b>N/A</b>	N/A

The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive income should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2019.

# SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

## UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2020

### CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	(UNAUDITED) As At 31 Dec 2020 RM'000	(AUDITED) As At 31 Dec 2019 RM'000
<strong>ASSETS</strong>		
<strong>NON-CURRENT ASSETS</strong>		
Property, plant and equipment	4,740	1,578
Right-of-use assets	966	446
Investment in associate	-	-
Contract assets	550	720
Deferred tax assets	369	-
	<strong>6,625</strong>	<strong>2,744</strong>
<strong>CURRENT ASSETS</strong>		
Trade receivables	3,006	4,405
Other receivables	432	583
Contract assets	197	914
Other investments	1,140	20
Cash and bank balances	1,426	620
	<strong>6,201</strong>	<strong>6,542</strong>
<strong>TOTAL ASSETS</strong>	<strong>12,826</strong>	<strong>9,286</strong>
<strong>EQUITY</strong>		
Share capital	6,302	1,700
Merger reserve	(1,450)	(1,450)
Retained earnings	569	3,031
Total Equity	<strong>5,421</strong>	<strong>3,281</strong>
<strong>LIABILITIES</strong>		
<strong>NON-CURRENT LIABILITIES</strong>		
Deferred tax liabilities	-	31
Lease liabilities	1,078	538
Bank borrowings	3,262	2,813
	<strong>4,340</strong>	<strong>3,382</strong>
<strong>CURRENT LIABILITIES</strong>		
Trade payables	1,378	589
Other payables	466	183
Contract liabilities	281	1,074
Amount owing to directors	135	74
Lease liabilities	183	68
Bank borrowings	387	256
Provision for taxation	235	379
	<strong>3,065</strong>	<strong>2,623</strong>
<strong>TOTAL LIABILITIES</strong>	<strong>7,405</strong>	<strong>6,005</strong>
<strong>TOTAL EQUITY AND LIABILITIES</strong>	<strong>12,826</strong>	<strong>9,286</strong>
<strong>NET ASSETS PER-SHARE (RM)</strong>	<strong>0.059</strong>	<strong>0.326</strong>

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2019.

# SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

## UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2020

### CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

<b>GROUP</b>	<b>ATTRIBUTABLE TO THE OWNERS OF THE PARENT</b>			<b>TOTAL EQUITY</b> RM'000
	<b>Non-distributable</b>		<b>Distributable</b>	
	<b>Share Capital</b> RM'000	<b>Merger Reserve</b> RM'000	<b>Retained Earnings/</b> RM'000	
<b>As at 1 Jan 2020</b>	<b>1,700</b>	<b>(1,450)</b>	<b>3,031</b>	<b>3,281</b>
Loss for the financial year, representing total comprehensive income for the financial year	-	-	(2,183)	<b>(2,183)</b>
<b>Transactions with owners:-</b>				
Issuance of ordinary shares	5,000	-	-	<b>5,000</b>
Share issuance expenses	(398)	-	-	<b>(398)</b>
<b>Total transactions with owners</b>	<b>4,602</b>	<b>-</b>	<b>-</b>	<b>4,602</b>
Final single-tier dividend for financial year ended 31 Dec 2019	-	-	(279)	<b>(279)</b>
<b>As at 31 Dec 2020</b>	<b>6,302</b>	<b>(1,450)</b>	<b>569</b>	<b>5,421</b>
<b>As at 1 Jan 2019</b>	<b>250</b>	<b>-</b>	<b>1,490</b>	<b>1,740</b>
Profit for the financial year, representing total comprehensive income for the financial year	-	-	1,541	<b>1,541</b>
<b>Transactions with owners:-</b>				
Adjustment pursuant to restructuring exercise before listing	1,450	(1,450)	-	-
Issuance of shares for the acquisition of a subsidiary	-	-	-	-
<b>Total transactions with owners</b>	<b>1,450</b>	<b>(1,450)</b>	<b>-</b>	<b>-</b>
<b>As at 31 Dec 2019</b>	<b>1,700</b>	<b>(1,450)</b>	<b>3,031</b>	<b>3,281</b>

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2019.

# SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

## UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2020

### CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	12 Months Ended 31 Dec 2020 (UNAUDITED) RM'000	12 Months Ended 31 Dec 2019 (AUDITED) RM'000
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
(Loss)/profit before taxation	(2,374)	1,950
Adjustments for:		
Depreciation of property, plant and equipment	245	150
Depreciation of right-of-use assets	171	9
Impairment loss on trade receivables	1,289	241
Unrealised loss on foreign exchange	5	-
Fixed assets written off	2	-
Share of associate results	120	-
Interest expenses	308	153
Interest income	(122)	(1)
<b>Operating (loss)/profit before working capital changes</b>	<b>(356)</b>	<b>2,502</b>
<b>Changes in working capital:</b>		
Trade & other receivables	260	(2,558)
Trade & other payables	1,068	(521)
Contract assets & liabilities	94	(252)
Amount owing to directors	61	(36)
	1,483	(3,367)
<b>Cash generated from/(used in) operations</b>	<b>1,127</b>	<b>(865)</b>
Interest paid	(180)	(154)
Interest received	122	1
Tax paid	(353)	(234)
	(411)	(387)
<b>Net cash generated from/(used in) operating activities</b>	<b>716</b>	<b>(1,252)</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Addition in other investment	(1,120)	(20)
Acquisition of an associate company	(120)	-
Purchase of property, plant and equipment	(3,530)	(220)
<b>Net cash used in investing activities</b>	<b>(4,770)</b>	<b>(240)</b>
<b>CASH FLOW FROM FROM FINANCING ACTIVITIES</b>		
Drawdown of borrowings	605	2,300
Repayment of borrowings	(154)	(120)
Proceed/(Repayment) of lease liabilities	87	(45)
Dividend paid	(279)	-
Proceeds from issuance of share capital, net of share issuance expenses	4,601	-
<b>Net cash generated from financing activities</b>	<b>4,860</b>	<b>2,135</b>
<b>Net increase in cash and cash equivalents</b>	<b>806</b>	<b>643</b>
<b>Cash and cash equivalents at beginning of the year</b>	<b>620</b>	<b>(23)</b>
<b>Cash and cash equivalents at end of the year</b>	<b>1,426</b>	<b>620</b>
<b>CASH AND CASH EQUIVALENTS AT END OF THE YEAR COMPRISES:</b>		
Cash and bank balances	1,426	620

The Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2019.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED  
31 DECEMBER 2020**

**PART A: EXPLANATORY NOTES IN COMPLIANCE WITH MALAYSIAN FINANCIAL  
REPORTING STANDARD (“MFRS”) 134: INTERIM FINANCIAL REPORTING**

**A1) Basis of preparation**

This interim financial statements have been prepared under the historical cost convention. This interim financial statements are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standards (“MFRS”) 134: Interim Financial Reporting and as well as Rule 6.12 and Appendix 6A of the LEAP Market Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”).

The interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2019 and the accompanying explanatory notes attached to this interim financial report.

**A2) Significant accounting policies and application of MFRS**

The accounting policies adopted are consistent with those of the previous financial year except the adoption of following standards and interpretations that are mandatory for the Group for the financial year beginning on 1 Jan 2020:-

<b>Description</b>	<b>Effective for annual periods beginning on or after</b>
Amendments to MFRS 3: Business Combinations (Definition of a business)	1 Jan 2020
Amendments to MFRS 101: Presentation of Financial Statements (Definition of material)	1 Jan 2020
Amendments to MFRS 108: Accounting Policies, Changes in Accounting Estimates and Errors (Definition of material)	1 Jan 2020
Amendments to References to the Conceptual Framework in MFRS Standards	1 Jan 2020
Amendments to MFRS 134: Interim Financial Reporting Amendments to MFRS 137: Provisions, Contingent Liabilities and Contingent Assets	1 Jan 2020



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**A2) Significant accounting policies and application of MFRS (Cont'd)**

The adoption of these new standards and interpretations did not have any material impact on the interim financial report of the Group.

The Group early adopted amendment to MFRS 16, "COVID-19-Related Rent Concessions" which exempts lessees from having to determine whether rent concessions on individual lease contracts as a direct consequence of the COVID-19 pandemic are lease modifications and allows lessees to account for such rent concessions as if they were not lease modifications.

As at the date of authorisation of this Condensed Report, the following Standards and amendments to Standards have been issued by the Malaysian Accounting Standards Board ("MASB") but are not yet effective:-

<b>Description</b>	<b>Effective for annual periods beginning on or after</b>
Amendments to MFRS Standards arising from Interest Rate Reform – Phase 2:- <ul style="list-style-type: none"><li>• Amendments to MFRS 4: Insurance Contracts</li><li>• Amendments to MFRS 7: Financial Instruments: Disclosures</li><li>• Amendments to MFRS 9: Financial Instruments</li><li>• Amendments to MFRS 16: Leases</li><li>• Amendments to MFRS 139: Financial Instruments: Recognition and Measurement</li></ul>	1 Jan 2021
Amendments to MFRS 3: Business Combinations – Reference to the Conceptual Framework	1 Jan 2022
Amendments to MFRS 101: Presentation of Financial Statements – Classification of Liabilities as Current or Non-current	1 Jan 2023
Amendments to MFRS 116: Property, Plant and Equipment – Proceeds before Intended Use	1 Jan 2022
Amendments to MFRS 137: Provisions, Contingent Liabilities and Contingent Assets – Onerous Contracts – Cost of Fulfilling a Contract	1 Jan 2022



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**A2) Significant accounting policies and application of MFRS (Cont'd)**

Description	Effective for annual periods beginning on or after
Annual Improvements to MFRS Standards 2018-2020:- <ul style="list-style-type: none"><li>• Amendments to MFRS 1: First-time Adoption of Malaysian Financial Reporting Standards</li><li>• Amendments to MFRS 9: Financial Instruments</li><li>• Amendments to MFRS 141: Agriculture</li><li>• Amendments to Illustrative Examples accompanying MFRS 16, "Leases"</li></ul>	1 Jan 2022
MFRS 17: Insurance Contracts Amendments to MFRS 17: Insurance Contracts	1 Jan 2023
Amendments to MFRS101 Presentation of Financial Statements – Classification of Liabilities as Current or Non-current	1 Jan 2023

Effective date of these Amendments to Standards has been deferred, and yet to be announced:-

Amendments to MFRS 10 Consolidated Financial Statements and MFRS 128 Investments in Associates and Joint Venture – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture.

The above pronouncements are either not relevant or do not have any impact on the financial statements of the Group.

**A3) Seasonal or cyclical factors**

The Group's performance is not significantly affected by seasonal and cyclical factors.

**A4) Unusual items**

Other than the different phases of Movement Control Order that were continuously imposed by Malaysia Government to curb the spread of COVID-19 disease from 18 March 2020 until to date, there were no unusual items affecting assets, liabilities, equity, net income or cash flows during the reporting period ended 31 Dec 2020.





**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**A5) Material changes in estimates**

There were no significant changes in the nature and amount of estimates reported in the prior interim period of the current financial period or prior years that have a material effect on the current financial period ended 31 Dec 2020 under review.

**A6) Debt and equity securities**

There were no issuance or repayment of debt and equity securities, share buy-backs, share cancellations, share held as treasury shares by the Group during the financial period.

**A7) Segmental reporting**

The Group's segmental report for the current financial period ended 31 Dec 2020 under review are as follows:-

**Revenue by Business Activities**

	Individual 6 Months Ended		Cumulative 12 Months Ended	
	31 Dec 2020	31 Dec 2019	31 Dec 2020	31 Dec 2019
	RM'000	RM'000	RM'000	RM'000
<b>REVENUE</b>				
Provision of integrated turnkey solutions	2,911	7,259	3,871	10,136
Provision of maintenance services	548	176	1,212	875
Others	50	-	50	-
<b>Total consolidated revenue</b>	<b>3,509</b>	<b>7,435</b>	<b>5,133</b>	<b>11,011</b>

**Revenue by Geographical Markets**

	Individual 6 Months Ended		Cumulative 12 Months Ended	
	31 Dec 2020	31 Dec 2019	31 Dec 2020	31 Dec 2019
	RM'000	RM'000	RM'000	RM'000
<b>REVENUE</b>				
Malaysia	3,509	7,067	5,133	10,643
Indonesia	-	368	-	368
<b>Total consolidated revenue</b>	<b>3,509</b>	<b>7,435</b>	<b>5,133</b>	<b>11,011</b>



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**A8) Valuation of property, plant and equipment**

There was no valuation on any of the Group's property, plant & equipment during the reporting period ended 31 Dec 2020.

**A9) Significant events**

There were no events of a material nature to be disclosed in the interim financial statements for the current financial period ended 31 Dec 2020.

**A10) Material changes in the composition of the Group**

There was no changes in the composition of the Group during the reporting period ended 31 Dec 2020, save and except for the followings:-

The wholly owed subsidiary of the Company, Supergenics Life Science Sdn Bhd ("SGLSSB") had on 6 Mar 2020 subscribed for additional 119,880 shares in Hope Stemcell Sdn Bhd ("HOPE"), with total shareholding of 12%.

Based on the shareholders' agreement of HOPE, SGLSSB is able to exert significant influence and be involved in the operation of HOPE and its' strategic plans. Accordingly, the Group has account the investment in HOPE as an associate and share the post acquisition financial results from HOPE under equity method.

**A11) Contingent liabilities and contingent assets**

There were no material contingent liabilities or assets for the reporting period ended 31 Dec 2020.

**A12) Material events subsequent to the end of the interim financial report**

The management is not aware of any material events subsequent to the end of the interim financial report that have not been reflected in the financial statements for the current financial report ended 31 Dec 2020 under review.

**A13) Capital commitment**

There was no commitment for the purchase of property, plant and equipment provided for in the current financial report ended 31 Dec 2020.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**PART B: ADDITIONAL INFORMATION REQUIRED UNDER THE LEAP MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD**

**B1) Review of performance**

**(i) 2<sup>nd</sup> Half Year, FY 2020 (“H2FY2020”) vs 2<sup>nd</sup> Half Year, FY 2019 (“H2FY2019”)**

	INDIVIDUAL		CUMULATIVE	
	6 Months Ended		YTD	
	31 Dec 2020	31 Dec 2019	31 Dec 2020	31 Dec 2019
	RM'000	RM'000	RM'000	RM'000
Revenue	3,509	7,435	5,133	11,011
Gross profit	1,564	2,545	1,796	3,613
Profit/(loss) before taxation	(1,600)	1,730	(2,374)	1,950

For the current financial period under review, the Group posted a revenue of RM3.51 million as compared to its corresponding preceding financial period, H2FY2019 of RM7.44 million. Along with the decrease in revenue, the Group had incurred loss before taxation of RM1.60 mil during the current period, as compared to its corresponding preceding financial period, H2 FY2019 profit before taxation of RM1.73 million.

The reduction in revenue was mainly due to the adverse impact resulted from the Covid-19 pandemic outbreak and the lower number of new cleanrooms development project secured by the Group. In addition, the Group's loss before taxation was also due to the one-off expenses amounting to RM1.86 million incurred from the Supergenics Group Berhad's listing on the LEAP Market which was completed on 6 January 2020 and the provision for impairment of trade receivables. Impact of RM0.17 million also arising from the MRF5 16 – Lease whereby the Group has entered into two new rental agreement for both office and factory during the financial year.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**B1) Review of performance (Cont'd)**

**(ii) Changes in revenue and PBT for H2FY2020 as compared with the immediate preceding period ended 30 Jun 2020 ("H1FY2020")**

	<b>Current</b>	<b>Immediate</b>	<b>Variance</b>
	<b>6 Months Ended</b>		
	<b>31 Dec 2020</b>	<b>30 Jun 2020</b>	
	RM'000	RM'000	%
Revenue	3,509	1,624	116.2
Gross profit	1,564	232	573.7
Loss before taxation	(1,600)	(774)	106.7

The Group has recorded a revenue of RM3.51 million with loss before tax of RM1.60 million for the 2<sup>nd</sup> half year ended 31 Dec 2020 as compared to the immediate preceding half year which recorded a revenue of RM1.62 million and loss before tax of RM0.77 million.

The Group's higher loss for the 2<sup>nd</sup> half year ended 31 Dec 2020 was mainly due to the provision for impairment of the trade receivable which in total amounted to RM1.29 million. Impact of RM0.17 million also arising from the MRFS 16 – Lease whereby the Group has entered into two new rental agreement for both office and factory during the financial year.

**B2) Future prospects**

The COVID-19 pandemic has adversely affected both local and global economies as well as consumer behaviour resulting in suspensions of businesses, imposition of travel restrictions and border controls.

In the third quarter, the Malaysian economy improved markedly following the gradual lifting of nationwide containment measures, as well as support from better external demand conditions. In line with the reopening of the economy from earlier COVID-19 containment measures and improving external demand conditions, the Malaysian economy recorded a smaller contraction of 2.7% in the third quarter. Improvements in growth were seen across most economic sectors, particularly in the manufacturing sector.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**B2) Future prospects (Cont'd)**

Based on the above, barring any further unforeseen circumstances and in view of the increasing Covid-19 cases in the country but tempered by the vaccination program started on 24 February 2021, the Company is working towards minimization of the impact on the existing and new project as a result of the implementation of different phases of Movement Control Order that were continuously imposed by Malaysia Government from 18 March 2020 until to date.

The Group will continue to expand our geographical reach and secure more cleanrooms development project as well as the provision of management services for cleanrooms. Our outstanding order book now stands at RM18.20 million and with total order book of RM25.12 million.

With the continuous monitoring of projects and the efforts put in by the management to date to improve our Group's processes and efficiency, the Board is cautiously optimistic for the Group's performance for the next financial year ended 31 December 2021.

**B3) Profit forecast, Profit Guarantee and Internal Targets**

The group has not issued any profit forecast, profit guarantee in any form of public documentation and announcement.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**PART C: OTHER INFORMATION**

**C1) Status of Corporate Proposal**

There were no corporate proposals announced but pending completion as at the date of this report.

**C2) Utilisation of Proceeds**

The proposed utilisation of proceeds from the fund raising of RM 5.0 mil are as follows:-

Description	Proposed Utilisation RM'000	Reallocation RM'000	Actual Utilisation RM'000	Balance RM'000	Timeframe for Utilisation Upon Listing
(I) Working Capital (1)	2,000	50	(2,050)	-	12 months
(II) Development of a showcase cleanroom	1,000	-	(1,000)	-	18 months
(III) Enhancement and development of Supergenics' Laboratory Monitoring and Controlling System	1,000	-	(1,000)	-	12 months
(IV) Estimated listing expenses (1)	1,000	(50)	(950)	-	Immediate
	<b>5,000</b>	<b>-</b>	<b>(5,000)</b>	<b>-</b>	

Note:-

(1) The surplus from estimated listing expenses was adjusted to the amount allocated for working

(2) The actual utilisation is up to the date of this report.

**C3) Material Litigation**

The management is not aware of any pending material litigation which will have a material effect on the financial position or the business of the Group and the Board is not aware of any proceedings pending or threatened against the Group or of any fact likely to give rise to any proceedings which may materially and adversely affect the financial position or business of the Group at the date of this report.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2<sup>ND</sup> HALF YEAR ENDED 31 DECEMBER 2020**

**C4) Dividends**

On 28 Aug 2020, the Company had paid final single tier dividend of RM0.003 per ordinary share in respect of the financial year ending 31 Dec 2019.

**C5) Earnings / (loss) per share**

	Individual		Cumulative	
	6 Months Ended		YTD	
	31 Dec 2020	31 Dec 2019	31 Dec 2020	31 Dec 2019
<b>a) <u>Basic earnings per-share</u></b>				
Loss attributable to the owners of parent ('000)	<b>(1,409)</b>	<b>1,361</b>	<b>(2,183)</b>	<b>1,541</b>
Total weighted average number of ordinary shares in issue ('000)	92,658	19,959	92,658	10,062
<b>Basic loss per share (sen)</b>	<b>(1.52)</b>	<b>6.82</b>	<b>(2.36)</b>	<b>15.31</b>
<b>b) <u>Diluted earnings per-share</u></b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>

**C6) Authorisation for issue**

The interim financial report were authorised for issue by the Board of Directors in accordance with resolution of the directors on 26 Feb 2021.